Premium
What is the most anticipated change induced by treatment using gender‐affirming hormones in individuals with gender incongruence?
Author(s) -
Masumori Naoya,
Baba Tsuyoshi,
Abe Teruo,
Niwa Koji
Publication year - 2021
Publication title -
international journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.172
H-Index - 67
eISSN - 1442-2042
pISSN - 0919-8172
DOI - 10.1111/iju.14499
Subject(s) - transgender , medicine , hormone therapy , transgender women , hormone , gender dysphoria , hormonal therapy , gender identity disorder , transgender person , clinical trial , gender identity , clinical psychology , gynecology , family medicine , breast cancer , psychology , men who have sex with men , cancer , social psychology , human immunodeficiency virus (hiv) , syphilis , psychoanalysis
Objectives To identify the most eagerly anticipated change resulting from hormone therapy using gender‐affirming hormones for patients with gender incongruence undergoing a clinical trial. Methods Patients diagnosed with gender identity disorders based on the International Classification of Diseases 10th revision classification at three institutions in Japan for whom hormone therapy using gender‐affirming hormones was initiated were analyzed. They were asked what the most anticipated change was due to gender‐affirming hormone that they had thought of between giving informed consent and the first administration of the drug. Results The responders were 336 transgender men who were administered androgens and 48 transgender women who received estrogens. The median age at commencement of hormone therapy was 24 years for transgender men and 28 years for transgender women. For transgender men, the most frequent answer was cessation of menses (52.7%) followed by a deepened voice (32.4%). For transgender women, breast development (35.4%) was the most anticipated change, followed by gynoid fat deposition (29.2%). Conclusions Cessation of menses in transgender men and breast development/gynoid fat deposition in transgender women might represent primary end‐points in clinical trials evaluating the efficacy of hormonal treatment in these patients.